TY - JOUR
T1 - Reducing the toxicity of cancer therapy
T2 - Recognizing needs, taking action
AU - Cleeland, Charles S.
AU - Allen, Jeff D.
AU - Roberts, Samantha A.
AU - Brell, Joanna M.
AU - Giralt, Sergio A.
AU - Khakoo, Aarif Y.
AU - Kirch, Rebecca A.
AU - Kwitkowski, Virginia E.
AU - Liao, Zhongxing
AU - Skillings, Jamey
N1 - Funding Information:
Symptoms. The meeting was sponsored by the C. Stratton Hill Colloquium on Pain and Its Relief. The individuals approached to participate in the colloquium were identified by the sponsors and were believed to be high-level stakeholders who could best research, advocate for and effect policy change toward understanding, managing and possibly eradicating the negative consequences of cancer treatment. These stakeholders attended from universities, hospitals, government agencies and pharmaceutical companies: The University of Texas MD Anderson Cancer Center, Baylor College of Medicine, Texas Oncology, Memorial Sloan–Kettering Cancer Center, National Cancer Institute (NCI), FDA, American Cancer Society, ASCO, American Society for Therapeutic Radiation Oncology, National Comprehensive Cancer Network, Oncology Nursing Society Foundation, National Coalition for Cancer Survivorship, National Center for Policy Analysis, National Patient Advocate Foundation, American Association for Cancer Research Survivorship Task Force, Lance Armstrong Foundation, Duke University Medical Center, Amgen, Pfizer, Genentech and Novartis.
PY - 2012/8
Y1 - 2012/8
N2 - Our understanding of the biology of cancer and the application of this knowledge to cancer treatment has greatly outpaced what we know of the biology underlying the symptoms and toxic effects that therapies produce. These adverse effects of therapy cause substantial discomfort and distress to patients and their families, limit treatment tolerability and can persist indefinitely in post-treatment survivorship. Despite these concerns, little research effort is targeted at documenting the nature of these effects. Similarly, limited efforts are being made in the drug-development arena to identify or develop treatments that might prevent or reduce toxicities. A panel of clinicians and researchers as well as representatives from advocacy groups, federal agencies and the pharmaceutical industry was convened to identify gaps in cancer treatment toxicity research and to provide direction for future action. With an emphasis on coordinating multidisciplinary efforts, this panel has presented a strategy to increase funding for the field and develop a coherent research agenda.
AB - Our understanding of the biology of cancer and the application of this knowledge to cancer treatment has greatly outpaced what we know of the biology underlying the symptoms and toxic effects that therapies produce. These adverse effects of therapy cause substantial discomfort and distress to patients and their families, limit treatment tolerability and can persist indefinitely in post-treatment survivorship. Despite these concerns, little research effort is targeted at documenting the nature of these effects. Similarly, limited efforts are being made in the drug-development arena to identify or develop treatments that might prevent or reduce toxicities. A panel of clinicians and researchers as well as representatives from advocacy groups, federal agencies and the pharmaceutical industry was convened to identify gaps in cancer treatment toxicity research and to provide direction for future action. With an emphasis on coordinating multidisciplinary efforts, this panel has presented a strategy to increase funding for the field and develop a coherent research agenda.
UR - http://www.scopus.com/inward/record.url?scp=84864464562&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84864464562&partnerID=8YFLogxK
U2 - 10.1038/nrclinonc.2012.99
DO - 10.1038/nrclinonc.2012.99
M3 - Review article
C2 - 22751283
AN - SCOPUS:84864464562
SN - 1759-4774
VL - 9
SP - 471
EP - 478
JO - Nature Reviews Clinical Oncology
JF - Nature Reviews Clinical Oncology
IS - 8
ER -